



Department of Defense US Army Medical Research and Materiel Command

Fiscal Year 2003 Ovarian Cancer Research Program Awards List

Table of Contents

Introduction

Fiscal Year 2003 Ovarian Cancer Research Program Funded Awards

RESEARCH AWARDS

Idea Development Awards

TRAINING AWARDS

New Investigator Awards

Fiscal Year 2003 Ovarian Cancer Research Program Participants

Peer Reviewers

Integration Panel Members

Glossary of Terms

INTRODUCTION

The US Army Medical Research and Materiel Command is pleased to present the award list of funded projects for the fiscal year 2003 (FY03) Ovarian Cancer Research Program. Award negotiations were completed by September 2004. The awards listed in this document were selected by a competitive two-tier review process. Funding decisions were based on scientific excellence as evaluated in the first tier of review, followed by programmatic relevance as judged in the second tier. These projects represent a diverse portfolio of scientific research in two program emphasis areas, etiology and early detection.

Congressional direction for FY03 specified \$10.0 million for ovarian cancer research. Following the receipt of funds, a programmatic strategy was developed, proposals were solicited and evaluated, awards were selected, and contract negotiations were completed. The FY03 programmatic strategy called for Ovarian Cancer Idea Development Awards and New Investigator Awards. The intent of the Idea Development Award is to encourage innovative approaches to ovarian cancer research, and the New Investigator Awards is intended to support postdoctoral fellows with at least 5 years of postdoctoral training and faculty through the level of Assistant Professor. FY03 funds are supporting 10 Idea Development Awards and 8 New Investigator Awards.

As the funded investigators embark on these projects, the Department of Defense and the US Army gratefully acknowledge the participation of their scientist, clinical, and consumer advisors. The expertise, vision, and diversity of perspectives of all individuals who contributed to this program were vital to developing a sound investment strategy on behalf of all persons affected by ovarian cancer. It is with great anticipation and excitement that we await the outcomes of this research.

Idea Development Awards

Log Number	PI Last Name	PI First Name	PI Organization	Title	Final Budget
OC030008	Haviv	Izhak	Peter MacCallum Cancer Institute	Regulation of Leukocyte Infiltration into Ovarian Cancer by Tumor-Stroma Interactions; a Microarray View of Cancer Microenvironment	\$359,480
OC030012	Dubeau	Louis	University of Southern California	Mechanism of Ovarian Epithelial Tumor Predisposition in Individuals Carrying Germline BRCA1 Mutations	\$609,162
OC030016	Smith	David	Mayo Foundation	PARK2, a Large Common Fragile Site Gene, Is Part of a Stress Response Network in Normal Cells that Is Disrupted during the Development of Ovarian Cancer	\$547,500
OC030036	Barnes	Mack	University of Alabama at Birmingham	A Controlled Trial of Chemoprevention Using COX-2 Inhibitors in an Avian Model of Spontaneous Ovarian Carcinogenesis	\$462,559
OC030053	Shridhar	Viji	The Mayo Clinic	Functional Characterization of a Novel Pro-Apoptotic Transcriptional Regulatory Protein in Ovarian Cancer	\$547,740
OC030065	Patriotis	Christos	Fox Chase Cancer Center	Mechanisms and Chemoprevention of Ovarian Carcinogenesis	\$635,729
OC030108	Sood	Anil	University of Texas M.D. Anderson Cancer Center	Role of EphA2 in Ovarian Cancer Development and Progression	\$565,935
OC030177	Baranowska-Kortylewi	Janina	University of Nebraska Medical Center	Cancer-Specific Compounds Regulated by the Cell Cycle for Therapy and Diagnosis of Ovarian Cancer	\$551,046
OC030163	Patankar	Manish	Eastern Virginia Medical School	Structural and Functional Analysis of CA125: Potential for Early Diagnosis and Understanding the Immune Evasion Strategies of Epithelial Ovarian Tumors	\$465,648
OC030180	Zhang	Zhen	Johns Hopkins Medical Institutions	Identification and Validation of Biomarkers for the Detection of Early-Stage Ovarian Cancer through Proteomic Profiling of Serum Samples from Multiple Centers	\$583,977

New Investigator Awards

Log Number	PI Last Name	PI First Name	PI Organization	Title	Final Budget
OC030067	Orsulic	Sandra	Harvard Medical School Massachusetts General Hospital	Epithelial-Stromal Interactions in Induction of Ovarian Cancer in a Mouse Model	\$497,100
OC030080	Connolly	Denise	Fox Chase Cancer Center	Modeling Human Epithelial Ovarian Cancer in Mice by Alteration of Expression of the BRCA1 and/or p53 Genes	\$508,621
OC030091	Fang	Xianjun	Virginia Commonwealth University	Role of Lysophosphatidic Acid in Neovascularization in Ovarian Cancer	\$450,000
OC030093	Suen	Ting-Chung	New York University School of Medicine	Cloning Transcriptional Repressors of BRCA1, Possible Roles in Sporadic Ovarian Cancer	\$507,000
OC030097	Wang	Yi	Baylor College of Medicine	Elucidating the Role of a Novel, Cancer-Causing Mutation of BRCA1 Phosphorylation in Genome Maintenance	\$448,852
OC030117	Schwartz	Donald	University of Michigan	Development and Characterization of a Murine Model of Ovarian Endometrioid Adenocarcinoma Induced by the Tissue-Specific Expression of Oncogenic beta-Catenin	\$436,010
OC030119	Eblen	Scott	University of Virginia	Identification and Characterization of MAP Kinase Substrates Involved in Growth Factor-Induced Ovarian Cancer Cell Proliferation, Invasion, and Metastasis	\$444,000

**Fiscal Year 2003 Ovarian Cancer Research Program
Peer Reviewers**

Peer Reviewers	Degree	Institution/Affiliation
Aldaz, Claudio	M.D., Ph.D.	University of Texas M.D. Anderson Cancer Center
Baker, Vicki	M.D.	Wayne State University
Batra, Surinder	Ph.D.	University of Nebraska Medical Center, Eppley Cancer Center
Beattie, Craig	Ph.D.	University of Nevada-Reno
Beck, William	Ph.D.	University of Illinois at Chicago
Benbrook, Doris	Ph.D.	University of Oklahoma Health Sciences Center
Britten, Richard	Ph.D.	Eastern Virginia Medical School
Cannon, Martin	Ph.D.	University of Arkansas for Medical Sciences
Chatterjee, Sunil	Ph.D.	University of Cincinnati
Coats, Steven	Ph.D.	Amgen, Inc.
Cohen, Marion	Ph.D.	University of Medicine and Dentistry of New Jersey
Daoud, Sayed	Ph.D.	Washington State University
Desprez, Pierre-Yves	Ph.D.	California Pacific Medical Center
Dubeau, Louis	M.D., Ph.D.	University of Southern California Norris Comprehensive Cancer Center
Eckhart, Walter	Ph.D.	The Salk Institute
Godwin, Andrew	Ph.D.	Fox Chase Cancer Center
Groden, Joanna	Ph.D.	University of Cincinnati
Haber, Roberta	Ph.D.	Scientific Review Administrator
Hartmann, Stacey		National Ovarian Cancer Coalition
Hellstrom, Ingegerd	M.D., Ph.D.	Pacific Northwest Research Institute
Hickey, Robert	Ph.D.	Indiana University School of Medicine
Hwu, Patrick	M.D.	National Institutes of Health
Jackson, Cynthia	Ph.D.	Rhode Island Hospital
Klostergaard, Jim	Ph.D.	University of Texas M.D. Anderson Cancer Center
Knutson, Keith	Ph.D.	University of Washington Tumor Vaccine Group
Kravit, Robyn		Ovarian Cancer National Alliance
Lau, Ching	M.D., Ph.D.	Texas Children's Hospital
Leung, Benjamin	Ph.D.	Scientific Review Administrator

Peer Reviewers	Degree	Institution/Affiliation
Malkas, Linda	Ph.D.	Indiana University School of Medicine
McCarty, Jr., Kenneth	M.D., Ph.D.	University of Pittsburgh
McIntosh, Martin	Ph.D.	Fred Hutchinson Cancer Research Center
Mercer, W. Edward	Ph.D.	Kimmel Cancer Institute, Thomas Jefferson University, Jefferson Medical College
Molina, Carlos	Ph.D.	University of Medicine and Dentistry of New Jersey - New Jersey Medical School
Moysich, Kirsten	Ph.D.	Roswell Park Cancer Institute
Muller, Carolyn	M.D.	University of Texas Southwestern Medical Center
Naschinski, Charlotte		Ovarian & Gynecological Cancer Coalition of Greater Washington
Naylor, Susan	Ph.D.	University of Texas Health Science Center at San Antonio
Ochieng, Josiah	Ph.D.	Meharry Medical College
Patriotis, Christos	Ph.D.	Fox Chase Cancer Center
Petricoin, Emanuel	Ph.D.	Food & Drug Administration – National Cancer Institute
Ramakrishnan, Sundaram	Ph.D.	University of Minnesota
Raylman, Raymond	Ph.D.	West Virginia University
Richard, Nyrvah		SHARE: Self Help for Women w/Breast or Ovarian Cancer
Rosen, Eliot	M.D., Ph.D.	Long Island Jewish Medical Center
Roy, Deodutta	Ph.D.	University of Alabama at Birmingham
Shen, Zhiyuan	Ph.D.	University of New Mexico School of Medicine
Skates, Steven	Ph.D.	Massachusetts General Hospital
Somplatsky-Jarman, Carol		Ovarian Cancer National Alliance
Soprano, Kenneth	Ph.D.	Temple University School of Medicine
Stack, Mary	Ph.D.	Northwestern University
Stone, Robin		Gilda's Club Metro Detroit
Talmadge, James	Ph.D.	University of Nebraska Medical Center
Taylor, Christopher	Ph.D.	Lombardi Cancer Center, Georgetown University Medical Center
von Gruenigen, Vivian	M.D.	Case Western Reserve
Worsham, Maria	Ph.D.	Henry Ford Health System

**Fiscal Year 2003 Ovarian Cancer Research Program
Integration Panel Members**

IP Member	Degree	Institution/Affiliation
Gershenson, David (Chair)	M.D.	University of Texas M.D. Anderson Cancer Center
Karlán, Beth (Chair Emeritus)	M.D.	Cedars-Sinai Medical Center
Alvarez, Ronald (Chair Elect)	M.D.	University of Alabama at Birmingham
Scroggins, Mary	M.A.	Ovarian Cancer National Alliance
Bell, Debra	M.D.	Massachusetts General Hospital
Boyd, Jeffrey	Ph.D.	Memorial Sloan-Kettering Cancer Center
Daly, Mary	M.D., Ph.D.	Fox Chase Cancer Center
Goldman, Patricia		Ovarian Cancer National Alliance
Hamilton, Thomas	Ph.D.	Fox Chase Cancer Center
Hricak, Hedvig	M.D., Ph.D.	Memorial Sloan-Kettering Cancer Center
Kohn, Elise	Ph.D.	National Cancer Institute
Markman, Maurie	M.D.	The Cleveland Clinic Foundation
Robinson, Elwood	Ph.D.	North Carolina Central University
Rubin, Stephen	M.D.	The University of Pennsylvania Medical Center

Glossary of Terms

Idea Development Award: As stated in the fiscal year 2003 (FY03) Ovarian Cancer Research Program (OCRCP) Program Announcement, the intent of the Idea Development Award is to encourage innovative approaches to ovarian cancer research. Idea Development Awards must address at least one of the program emphasis areas (i.e., etiology or early detection). Investigators from all academic levels were eligible to submit proposals; however, preliminary data relevant to ovarian cancer research and the proposed project was required. Evidence of institutional support and commitment to foster the applicant's research career, such as the provision of access to adequate laboratory facilities and equipment was necessary.

New Investigator Award (NIA): As stated in the fiscal year 2003 (FY03) Ovarian Cancer Research Program Announcement, the intent of the New Investigator Award was to recognize and support postdoctoral fellows with at least 5 years of postdoctoral training and faculty through the level of Assistant Professor. This mechanism encouraged investigators with innovative ideas applicable to the etiology and/or early detection of ovarian cancer to apply; however, no preliminary data was required.